Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Andrographolide, a major bioactive compound from the plant Andrographis paniculata, has a long history of use in traditional medicine systems, particularly in Asia, for treating respiratory infections including bronchitis. In recent years, scientific studies have investigated its efficacy and mechanisms.

Several randomized controlled trials (RCTs) and meta-analyses have assessed the use of standardized Andrographis paniculata extracts (which contain andrographolide) for acute respiratory tract infections, including bronchitis. Some meta-analyses (e.g., Poolsup et al., 2004; Coon & Ernst, 2004; Hu et al., 2017) conclude that Andrographis may reduce symptom severity and duration in acute bronchitis compared to placebo, with effects similar to conventional treatments. The proposed mechanisms include anti-inflammatory, immunomodulatory, and antiviral actions attributed to andrographolide.

However, many studies have methodological limitations, such as small sample sizes and heterogeneity in dosing and extract standardization. While evidence supports symptom relief (especially cough and sore throat) in uncomplicated acute bronchitis, the data are insufficient to recommend it as a standalone or first-line therapy. Regulatory agencies and clinical guidelines typically do not endorse andrographolide for bronchitis, but it is considered a possible adjunct.

In summary, there is moderate-quality scientific evidence (rated as 3/5) suggesting that andrographolide-containing extracts may offer symptomatic relief in acute bronchitis, though more rigorous trials are needed to confirm efficacy and safety.

More about Andrographolide
More about Bronchitis

Other ingredients used for Bronchitis

Other health conditions supported by Andrographolide

Products containing Andrographolide